Bank of Nova Scotia Grows Stock Holdings in Eli Lilly and Company $LLY

Eli Lilly posted a strong quarter, reporting $7.02 EPS versus $6.42 expected and revenue of $17.60 billion versus $16.09 billion (revenue +53.9% YoY), with ROE of 109.52% and net margin of 30.99%. Management set FY2025 EPS guidance of $23.00–$23.70 (analysts at ~23.48) while several brokers raised ratings and targets, and institutional ownership remains high (82.53%); Bank of Nova Scotia modestly increased its stake to 248,260 shares (~$193.5M). Shares trade around $1,009 with a $954.13B market cap, a quarterly dividend of $1.50 ($6.00 annualized, 0.6% yield) and technicals showing 50-/200-day averages of $918.84 and $810.35 respectively.

Analysis

Market structure: Eli Lilly (LLY) is a clear near-term winner from strong GLP‑1/diabetes demand—Q3 revenue +53.9% YoY, net margin ~31% and FY25 EPS guide 23.0–23.7 implies continued high-margin growth. Competitive losers are smaller diabetes/obesity specialists and payors facing higher claim costs; pricing power is intact but already priced into a ~49x PE and $954B market cap, so incremental share gains must come from sustained unit growth, not multiple expansion.

Risk assessment: Key tail risks are regulatory/pricing intervention on GLP‑1s (estimate 10–25% probability over 12–24 months), unexpected manufacturing or supply constraints, and faster-than-expected payer pushback that compresses gross margins >300bp. Immediate (days/weeks) risks include earnings/analyst reactions and IV repricing; short-term (3–12 months) hinges on CMS/payer statements and competitor label wins; long-term (2–5 years) depends on reimbursement and novel indications uptake.

Trade implications: Tactical: establish a modest long exposure to LLY (2–4% portfolio) now and add on weakness to the 200‑day MA (~$810) or if EPS guide is raised >+0.7 to >24.0 for FY25. Use defined‑risk options: buy Jan 2026 1000/1400 call spread size = 1% notional to capture upside while capping premium. Pair trade: long LLY vs short XBI (equal dollar) to capture large‑cap biotech outperformance while hedging idiosyncratic small‑cap risk.

Contrarian angles: Consensus buys (avg PT $1,087) underweight regulatory shock and payor negotiation risk; if CMS signals price controls or formulary exclusions, a >20% drawdown is plausible and currently under-hedged. Conversely, if LLY reports successive quarters with >40% revenue growth and raises FY25 EPS above 24.0, multiple re‑rating to MS target ~$1,290 is credible—trade both outcomes with asymmetric option structures and concrete stop/triggers.

Key Decisions for Investors

• Establish a 2–4% long position in LLY (equity) immediately; size to 3% if purchase price < $1,000; add up to +2% on a pullback to the 200‑day MA (~$810).
• Buy a defined‑risk call spread (LLY Jan 2026 1000/1400 call spread) sized to 1% of portfolio notional to capture upside to $1,400 while limiting premium outlay.
• Implement a hedged pair: long LLY equal‑dollar vs short XBI (ETF) equal‑dollar to isolate large‑cap GLP‑1 secular upside and hedge sector-specific biotech volatility; rebalance monthly.
• Trim or stop‑loss: reduce LLY exposure by 50% if FY25 EPS guide falls below 22.0 or if reported gross margin contracts >300 basis points; tighten if news shows CMS/Medicare pricing action within 90 days.
• Watch specifically: CMS/payer statements and competitor label/launch updates over next 90–180 days and quarterly revenue growth trends; if sequential revenue growth slips below +30% YoY, reduce position by another 25%.